Visterra Licenses Dengue IP From MIT, Tops Off Series A To $34.2 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech plans to file an IND for its lead antibody candidate in seasonal and pandemic flu in early 2014. It also will optimize MIT research into dengue virus to find a clinical candidate to treat dengue fever.
You may also be interested in...
Flu Fighter Visterra Tops Up Series A Round With Cash From Gates
To help push an antibody flu treatment into the clinic, the biotech has added $13 million from The Gates Foundation and others to bring total Series A funding to $26 million.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.